Fig. 2From: Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in SpainLong-term health outcomes associated to testing-ROS1 and to no-testing ROS1 strategies, base case. a Health outcomes expressed in total PF-LYs and total LYs; b Health outcomes expressed in total QALYs. ROS1: c-ros oncogene 1; PF:Progression-free life years; LY: life years; QALY: quality-adjusted life yearsBack to article page